Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adulteration meeting set

This article was originally published in The Tan Sheet

Executive Summary

FDA schedules a May 1 public meeting to discuss methods for better predicting and preventing economically motivated adulteration of regulated products. The meeting in College Park, Md., will address what industry is doing and could do to prevent EMA. FDA, the U.S. Pharmacopeia and industry stakeholders are revising analytical testing standards to effectively screen for contaminated heparin, diethylene glycol in glycerin and melamine in infant formula - recent instances of EMA (1"The Tan Sheet" Feb. 16, 2009, p. 16)

You may also be interested in...



U.S. Pharmacopeia Moves Melamine Testing Into The 21st Century

U.S. Pharmacopeia is developing a protein testing method that cannot be "tricked" by contaminants such as melamine, unlike the existing standard for analysis

3D Carbon Partners With Resolution Medical To Produce More Than 1 Million Nasal Swabs A Week

Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs to address the shortage for COVID-19 testing.

ACC 2020: Medtronic’s Evolut TAVR Works In Low-Risk Bicuspid Study

Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.

Topics

UsernamePublicRestriction

Register

PS102766

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel